cd123-car-nk cells
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2022 (NCT05574608)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06690827 | Phase 1 | Nov 13, 2024 | Chongqing Precision Biotech Co., Ltd |
| NCT06006403 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2023 | Chongqing Precision Biotech Co., Ltd, Shanxi Bethune Hospital |
| NCT05574608 | Early Phase 1 (Phase 1) | Oct 1, 2022 | Government of China, People's Liberation Army of China |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chongqing Precision Biotech Co., Ltd | For profit | 2 | 2 | 2 | 2023 |
| Government of China | Government | 1 | 0 | 1 | 2022 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2022 |
| Shanxi Bethune Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1